Could Marijuana Stock GW Pharmaceuticals Soar More Than 50%?
GW Pharmaceuticals (NASDAQ: GWPH) used to be a high-flying marijuana stock. The cannabinoid-focused biotech captured investors' attention with overwhelmingly positive clinical studies of cannabidiol (CBD) product Epidiolex in treating two rare forms of epilepsy.
But much of the sizzle for GW Pharmaceuticals has now fizzled out. The biotech's shares are down a bit so far in 2017. However, at least one Wall Street investment firm thinks that GW Pharmaceuticals stock has plenty of room to run. Cowen and Company recently issued a price target for the stock of $165, more than 50% higher than the current share price. Can GW Pharmaceuticals really soar by that much?
Image source: Getty Images.
Source: Fool.com
